Abstract. Thymic epithelial tumors (TETs) consist of a series of neoplasm that differ morphologically and biologically. Due to its rarity and indolent natural history, large-scale prospective trials have been lacking. This study aimed to evaluate long-term clinical outcomes and clinicopathologic features for TET after surgical resection and adjuvant treatments. One hundred patients who received surgery plus adjuvant radiotherapy ± chemotherapy for TET (Masaoka stage II-IVa) from 1995 to 2005 were retrospectively reviewed. Masaoka staging systems were adopted, and pathologic results were classified according to World health organization (WHO) histologic classification. After surgery, 55 patients were treated with radiotherapy alone, while 45 with radiotherapy and chemotherapy. The median radiation dose was 50.4 Gy (45-63 Gy) and six cycles of chemotherapy, consisting of doxorubicin, cisplatin, vincristine and cyclophosphamide, were applied every 3-4 weeks. Distributions according to Masaoka stage were as follows; stage II (58 patients), III (21) and IVa (21). According to WHO histology, there were A (3), AB (7), B1 (7), B2 (31), B3 (31) and C (21). With a median follow-up duration of 65 months (8-143 months), the 5-year overall survival (OS) and diseasefree survival (DFS) rates were 75.7% (89.2, 67.9 and 52.1% in stage II, III and IVa, respectively) and 70.3% (83, 62.4 and 33.6% in stage II, III and IVa, respectively). In multivariate analysis, prognostic factors for OS were age, WHO histology, Masaoka stage, and recurrence, while pleural involvement, WHO histology, and Masaoka stage had significant impacts on DFS. Adjuvant chemotherapy did not alter survival outcomes and recurrence patterns. Pleura was the most common recurrence site (15 patients, 53.6%), and significantly associated with pleural recurrence-free survival. In conclusion, pleural involvement at diagnosis was the important prognostic factor, in addition to WHO histology and Masaoka stage. To prevent pleural recurrence and prolong survival, innovative therapeutic approaches warrant further investigations.
Introduction
Thymic epithelial tumor (TET) consists of a series of neoplasm that differ morphologically as well as biologically. It is a rare primary tumor of the anterior mediastinum, which accounts for 20-30% of all mediastinal neoplasms and 1% of all reported cancers. Its annual incidence is only 0.15 cases per 100,000 in the United States and due to its rarity and indolent natural history, large-scale prospective randomized trials have been lacking (1, 2) . Five-year overall survival (OS) rates of 90-94% and 86-95% were reported after curative resection for stage I and II tumors, respectively, while stage III and IV patients experienced 5-year OS rates of 56-69% and 11-50%, respectively (3, 4) .
Wide controversies to determine the terminology and classification of TETs existed in the past. Only recently provisional consensus on staging and histologic classifications have been reached (3) . Two major factors leading to this consensus building are the current World Health Organization (WHO) criteria for histologic classification, and the suggestion of a modified Masaoka staging system.
Regarding treatment modalities, although surgery remains the mainstay of treatment, adjuvant chemotherapy or radiotherapy has been widely used in many institutes (4, 5) . Nowadays, many oncologists adopt postoperative mediastinal irradiation as standard for the majority of stage II or higher tumors, even after complete resection (6) (7) (8) (9) . However, despite postoperative radiotherapy, >80% of recurrences still occur Histologic classification and clinical staging. Pathologic results were confirmed by one experienced pathologist who was blind to the clinical data, according to the WHO histologic classification. Hematoxylin and eosin-stained sections were available, and at least five sections were examined for histologic typing of the tumor for every patient. Additional sections were examined if a microscopically positive margin was suspected. The stage was determined by review of the surgical and pathologic reports, and the staging system of Masaoka et al (11) was adopted.
Surgery. Surgical procedures included complete removal of thymic, mediastinal fat tissue, and any suspicious lesions. Furthermore, we performed an exploration of the entire thorax, including both pleural cavities, via median sternotomy to determine if satellite lesions were present, and to confirm that no secondary neoplasms were present. Surgeons tried to completely remove all the involved pleural and pericardial lesions, if surgically possible, even in patients with stage IVa tumor.
Adjuvant chemotherapy. The ADOC regimen was used for a total of six cycles every 3-4 weeks, and consisted of doxorubicin (40 mg/m 2 ) and cisplatin (50 mg/m 2 ) administered intravenously on day 1, vincristine (0.6 mg/m 2 ) on day 3, and cyclophosphamide (700 mg/m 2 ) on day 4. The first three cycles of chemotherapy were initiated within 4 weeks after surgery, followed by radiotherapy and then a further three cycles of chemotherapy.
Adjuvant radiotherapy. Radiotherapy was administered with a 10-MV linear accelerator in a three-way manner (anterior/ right anterior oblique/left anterior oblique) after computed tomography (CT). The irradiation field that covered the primary tumor bed with a margin of ~1-2 cm was applied to the entire population at the median target dose of 5040 cGy (180 cGy/fraction) for 5-6 weeks. A similar method was applied to patients with stage IVa tumors, taking into consideration preoperative radiological studies and intraoperative findings on the extent of the tumor; the scheduled doses were slightly higher (5400-6300 cGy) according to the decision of the radiation oncologists. Prophylactic irradiation to the supraclavicular fossae was not performed. Irradiation to the thorax was started within at least 5 weeks from the date of operation. In patients given adjuvant chemotherapy, it was started after three cycles of chemotherapy, that is, within 4 or 5 months after surgery.
Initial workup and follow-up. Initial evaluation included a complete history and physical examination with special attention to symptoms often associated with TETs; laboratory procedures included a complete blood cell count, blood urea nitrogen, creatinine and liver function tests. Chest radiography and CT were also included in the initial workup, and chest magnetic resonance imaging was performed, if necessary, to assess the involvement of major vessels and surrounding organs.
Follow-up chest CT was performed within 4-6 weeks following completion of radiotherapy. These imaging studies were also performed after each three cycles of chemotherapy. After completion of scheduled adjuvant treatment, patients were seen at 6-month intervals, and chest CT, whole-body bone scanning, and laboratory tests (similar to the initial workup) were performed at each visit.
Routine assessment of cardiac function before and after chemotherapy was not performed unless patients presented with major symptoms and signs of heart failure because they received a relatively lower cumulative dose of doxorubicin (240 mg/m 2 during six cycles) (12) . Toxicity was graded according to the Common Toxicity Criteria of the National Cancer Institute, version 1.0 or 2.0 (available from http://ctep.info.nih.gov/reporting/ctc.html).
Statistical analysis. Univariate analysis was performed by the Kaplan-Meier method to assess prognostic factors for OS and disease-free survival (DFS), with comparison using a logrank test for initial analysis. Subsequent multivariate analysis was performed using the Cox regression model to identify independent prognostic factors. Differences in continuous variables were statistically examined with Student's t-test, and those of the categorical variables using the χ 2 test. OS was measured from the date of operation until the day of death or last follow-up visit. DFS was also measured from the date of operation until the date of recurrence. A P-value of 0.05 was chosen for statistical significance. Statistical analysis was performed using SPSS software version 12.0 (SPSS, Chicago, IL, USA).
Results
Baseline clinical characteristics. Patient characteristics are summarized in Table I 
OP, operation; RT, radiotherapy; CT, chemotherapy. 
-------------------------------------------------
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II III IVa Total  ------------------------------------------------ invasion (P=0.007) were identified as independent prognostic factors in multivariate analysis (Table III; Figs. 1 and 2) .
------------------------------------------------
Patterns of recurrence. Recurrence was observed in 28 patients (28%), with a median survival of 10.8 months after recurrence. Patterns of recurrence are described in Table IV . Only two patients (7.1%) experienced intra-radiation field recurrence. Among the extra-radiation field recurrences, the pleura was the most frequent site of treatment failure (15 patients, 53.6%), followed by the lung (11 patients, 39.3%). Of 15 pleural recurrences, 11 patients (73.3%) had pleural dissemination remote from the primary tumor bed and irradiation field. Ten patients experienced only pleural recurrence, and five had simultaneous recurrences in the pericardium (n=2), mediastinum (n=1) and lung (n=2). Three patients experienced distant metastasis (two in the liver and one in bone).
Pleural recurrence. When tumors recurred, pleural invasion at the time of surgery predicted the higher overall incidence of pleural involvement (23.2% in pleura-positive versus 8.7% in pleura-negative patients; P=0.021). Furthermore, pleural Table III . Prognostic factors affecting 5-year overall survival and disease-free survival. 
-----------------------------------------------------------------------------------------------------Overall survival Disease-free survival ----------------------------------------------------------------------
----------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------
a Data are expressed as p-value. OP, operation; RT, radiotherapy; CT, chemotherapy. Table IV . Patterns of recurrences.
Site of recurrences
RT, radiotherapy; CT, chemotherapy.
a In patients with two sites of first recurrence, both sites were scored.
-
invasions at diagnosis led to longer pleural recurrence-free survival (Fig. 3) .
Management after recurrence. Recurrent TET was treated with a palliative approach, except in three patients who did not receive any treatment due to poor performance status or treatment refusal. Seven patients underwent surgical resection in combination with chemotherapy or radiotherapy. Fifteen patients received only chemotherapy, one only radiotherapy and two received both. The ADOC regimen was applied as palliative chemotherapy for eight chemotherapy-naive patients, and taxane-based combination regimens for seven patients who were previously treated with the ADOC regimen.
Treatment toxicity. In terms of radiation toxicity, all patients completed the scheduled radiotherapy without major complications. No patients reported any late toxicity. The ADOC regimen was well tolerated (Table V) . Among grade III/IV hematologic toxicity, only neutropenia was observed in 21 patients (46.7%), without anemia or thrombocytopenia. Common non-hematologic toxicity included alopecia (100%), fatigue (60%) and nausea/vomiting (53/ 51%). The only grade III/IV non-hematologic toxicity was nausea/vomiting (26/24%). No treatment-related mortality occurred, and all patients completed the six cycles of ADOC chemotherapy without dose reduction. Four cases (8.8%) of chemotherapy delay occurred due to grade III/IV neutropenia (n=3) and nausea/vomiting (n=1).
Discussion
TET is a kind of neoplasm including tumors that differ morphologically as well as biologically and only recently provisional consensus on staging and histologic classifications have been reached. On treatment strategies, complete surgical resection is the treatment of choice for TETs and the most important indicator of long term prognosis (13) (14) (15) . However, intrathoracic recurrences have been reported in approximately 28-57% of patients with stage II and III tumors, therefore, most centers currently consider postoperative radiotherapy except for patients with stage I disease. Furthermore, to prevent the extra-radiation field, additional adjuvant treatments, including chemotherapy, have been tried despite some controversy (6) (7) (8) (13) (14) (15) (16) (17) .
In the present study, we investigated the correlation between the WHO histologic subtypes and the Masaoka staging system, and identified these as two independent 
Toxicities were assessed by the Common Toxicity Criteria of the National Cancer Institute, version 1.0 or 2.0.
prognostic factors for survival, similar to those of other investigations (3, 4, 8, (18) (19) (20) (21) . Interestingly, we found the importance of the pleural factor, in addition to Masaoka stage, especially for DFS. As pleural-based recurrence is the most common pattern of failure, and is closely correlated with the incidence of pleural involvement at diagnosis, it may be a strong predictor for DFS, in addition to the Masaoka stage (22, 23) . Actually, pleural involvement at diagnosis was significantly correlated with pleural recurrence-free survival. This also suggests that some patients with pleural involvement at diagnosis may already have latent microscopic pleural dissemination at the time of surgery, even in lower stage disease (10, 22) .
In contrast to previous studies, a positive resection margin did not independently influence OS and DFS on multivariate analysis (2, 16, 24, 25) . Since complete resection was significantly higher in stage II than in stage III/IVa, the final influence on survival may be determined more accurately by clinicopathologic status rather than by resection status alone (26) . Furthermore, adequate postoperative radiotherapy may overcome the burden of microscopic residual disease in the primary tumor bed (8, 9, 21) .
The ADOC single chemotherapy regimen was used in our study. It is regarded as highly active and well tolerated, demonstrating overall response rate of 50-80% for unresectable or metastatic TET and excellent compliance (4, 14, 27, 28) .
No toxic deaths were observed and each patient completed the scheduled six cycles of chemotherapy with manageable toxicity.
Considering the high response rate of the ADOC regimen, and the chemo-sensitivity of TETs, there may be a potential rationale for using adjuvant chemotherapy to prevent extraradiation field recurrence, and prolong survivals (4, 10, 14, 15) . However, adjuvant chemotherapy did not alter the survival outcomes and recurrence patterns in our study. The potential reasons for this lack of additional benefit are as follows; first, given the relatively small number of recurrences and considering the indolent nature of TETs, it is difficult to accurately validate the efficacy of chemotherapy (2). Second, considering that the pleura is the most frequent site of recurrence, systemic administration of chemotherapeutic agents might not be sufficient to maintain adequate drug concentrations in the pleural cavity (29) (30) (31) . Large-scale prospective trials are needed to more accurately assess the role of adjuvant chemotherapy.
In conclusion, although there was a clear association between two systems, the Masaoka stage and WHO histotype were independent prognostic factors for survival. Furthermore, pleural involvement at diagnosis was another significant prognostic variable for recurrence. As the most common patterns of recurrence occurred in the extra-radiation field, that is, pleura, large-scale prospective trials on more innovative therapeutic approaches are needed to reduce pleural recurrence and prolong survival.
